FOXD2‑AS1 overexpression enhanced the viability and metastasis of HCC cells in vitro and in vivo, as revealed by MTT, wound healing and cell migration assays.
Our findings suggest FOXD2-AS1 functions as an oncogene and promotes the tumor progression and metastasis in PTC, which might serve as a promising prognostic biomarker and potential therapeutic target for PTC patients.
The pooled ORs indicated that FOXD2-AS1 upregulation was related to large tumor size (OR = 1.53, 95%CI: 1.26-1.85, p < 0.001), deep invasion depth (OR = 1.99, 95%CI: 1.53-2.58, p < 0.001), distant metastasis (OR = 2.03, 95%CI: 1.69-2.43, p < 0.001) and advanced TNM stage (OR = 1.35, 95%CI: 1.06-1.72, p = 0.0150), but not to lymph node metastasis nor differentiation.
Furthermore, high expression of FOXD2-AS1 was obviously correlated with deep Breslow thickness, present ulceration, high Clark level and distant metastasis in cutaneous melanoma patients.